Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 9/20 | 0.68 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | SI | P14410 | 4/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001074 | 0.83 | ACACB (0.80) | ACACBGAAMAPTSMN1; SMN2 | |
| SCHEMBL29675650 | 0.82 | ACACB (0.86) | ACACBGAAMAPTSMN1; SMN2 | |
| SCHEMBL256437 | 0.81 | ACACB (1.00) | ACACB | |
| SCHEMBL12001196 | 0.78 | ACACB (0.68) | ACACB | |
| SCHEMBL12001189 | 0.76 | ACACB (0.69) | ACACB | |
| SCHEMBL256438 | 0.76 | ACACB (1.00) | ACACB | |
| SCHEMBL18311338 | 0.73 | GAA (0.48) | CYP1A1CYP1B1MGAMGAASI | |
| SCHEMBL18311339 | 0.72 | GAA (0.56) | CYP1A1CYP1B1MGAMGAASI | |
| SCHEMBL12001285 | 0.69 | ACACB (0.73) | ACACB | |
| SCHEMBL9525740 | 0.69 | THRA (0.54) | ACACBCYP1A1CYP1B1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885CYP1A1 1514/4885CYP1B1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.